Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy

Mikkel Fode; Peter Busch Østergren; Christian Fuglesang S Jensen; Henrik Jakobsen; Jens Sønksen

doi:10.1080/21681805.2017.1387603

Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy

Mikkel Fode, Peter Busch Østergren, Christian Fuglesang S Jensen, Henrik Jakobsen, Jens Sønksen

Institut for Klinisk Medicin

1 Citationer (Scopus)

Abstract

OBJECTIVE: Erectile dysfunction (ED) is common following radical prostatectomies, and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are generally considered the first choice of treatment. The purpose of this study was to analyze the long-term efficacy of PDE5 inhibitors in a group of men who did not achieve sufficient erectile function from the medication in the short term following surgery.

MATERIALS AND METHODS: Prospectively collected data from patients with postprostatectomy ED, initial failure of PDE5-inhibitor treatment at 3 and/or 6 months and at least 12 months' follow-up were included. All patients had completed the International Index of Erectile Function short-form questionnaires (IIEF-5) before surgery and at follow-up visits. Response to PDE5 inhibitors was defined as an IIEF-5 score of at least 17.

RESULTS: The inclusion criteria were fulfilled by 349 patients. At 12 months, 228 patients were still using PDE5 inhibitors. Of these patients, 92 had undergone bilateral and 120 had undergone unilateral nerve-sparing radical prostatectomies. Overall, 42 PDE5-inhibitor users (18%) were responders at 12 months. Bilateral nerve sparing was the only independent predictor of a late response (odds ratio = 2.9). Thus, 28% of bilaterally nerve-spared patients were responders, while corresponding numbers for unilaterally nerve-spared patients and non-nerve-spared patients were 13% and 6%, respectively.

CONCLUSIONS: Patients who have undergone bilateral nerve-sparing radical prostatectomy should be rechallenged periodically with PDE5 inhibitors even if the treatment is unsuccessful initially. Unilaterally nerve-spared patients and especially non-nerve-spared patients are likely to need more aggressive treatment.

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Urology
Vol/bind	52
Udgave nummer	2
Sider (fra-til)	108-110
ISSN	0036-5599
DOI	https://doi.org/10.1080/21681805.2017.1387603
Status	Udgivet - 4 mar. 2018

Adgang til dokumentet

10.1080/21681805.2017.1387603

Citationsformater

@article{ba510ecb4cdf4b4eb8e5832cddc31674,

title = "Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy",

abstract = "OBJECTIVE: Erectile dysfunction (ED) is common following radical prostatectomies, and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are generally considered the first choice of treatment. The purpose of this study was to analyze the long-term efficacy of PDE5 inhibitors in a group of men who did not achieve sufficient erectile function from the medication in the short term following surgery.MATERIALS AND METHODS: Prospectively collected data from patients with postprostatectomy ED, initial failure of PDE5-inhibitor treatment at 3 and/or 6 months and at least 12 months' follow-up were included. All patients had completed the International Index of Erectile Function short-form questionnaires (IIEF-5) before surgery and at follow-up visits. Response to PDE5 inhibitors was defined as an IIEF-5 score of at least 17.RESULTS: The inclusion criteria were fulfilled by 349 patients. At 12 months, 228 patients were still using PDE5 inhibitors. Of these patients, 92 had undergone bilateral and 120 had undergone unilateral nerve-sparing radical prostatectomies. Overall, 42 PDE5-inhibitor users (18%) were responders at 12 months. Bilateral nerve sparing was the only independent predictor of a late response (odds ratio = 2.9). Thus, 28% of bilaterally nerve-spared patients were responders, while corresponding numbers for unilaterally nerve-spared patients and non-nerve-spared patients were 13% and 6%, respectively.CONCLUSIONS: Patients who have undergone bilateral nerve-sparing radical prostatectomy should be rechallenged periodically with PDE5 inhibitors even if the treatment is unsuccessful initially. Unilaterally nerve-spared patients and especially non-nerve-spared patients are likely to need more aggressive treatment.",

keywords = "Aged, Erectile Dysfunction/drug therapy, Humans, Male, Middle Aged, Organ Sparing Treatments/methods, Peripheral Nerves, Phosphodiesterase 5 Inhibitors/administration & dosage, Postoperative Complications/drug therapy, Prostatectomy/adverse effects, Retreatment, Surveys and Questionnaires, Time Factors",

author = "Mikkel Fode and {\O}stergren, {Peter Busch} and Jensen, {Christian Fuglesang S} and Henrik Jakobsen and Jens S{\o}nksen",

year = "2018",

month = mar,

day = "4",

doi = "10.1080/21681805.2017.1387603",

language = "English",

volume = "52",

pages = "108--110",

journal = "Scandinavian Journal of Urology",

issn = "0036-5599",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy

AU - Fode, Mikkel

AU - Østergren, Peter Busch

AU - Jensen, Christian Fuglesang S

AU - Jakobsen, Henrik

AU - Sønksen, Jens

PY - 2018/3/4

Y1 - 2018/3/4

N2 - OBJECTIVE: Erectile dysfunction (ED) is common following radical prostatectomies, and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are generally considered the first choice of treatment. The purpose of this study was to analyze the long-term efficacy of PDE5 inhibitors in a group of men who did not achieve sufficient erectile function from the medication in the short term following surgery.MATERIALS AND METHODS: Prospectively collected data from patients with postprostatectomy ED, initial failure of PDE5-inhibitor treatment at 3 and/or 6 months and at least 12 months' follow-up were included. All patients had completed the International Index of Erectile Function short-form questionnaires (IIEF-5) before surgery and at follow-up visits. Response to PDE5 inhibitors was defined as an IIEF-5 score of at least 17.RESULTS: The inclusion criteria were fulfilled by 349 patients. At 12 months, 228 patients were still using PDE5 inhibitors. Of these patients, 92 had undergone bilateral and 120 had undergone unilateral nerve-sparing radical prostatectomies. Overall, 42 PDE5-inhibitor users (18%) were responders at 12 months. Bilateral nerve sparing was the only independent predictor of a late response (odds ratio = 2.9). Thus, 28% of bilaterally nerve-spared patients were responders, while corresponding numbers for unilaterally nerve-spared patients and non-nerve-spared patients were 13% and 6%, respectively.CONCLUSIONS: Patients who have undergone bilateral nerve-sparing radical prostatectomy should be rechallenged periodically with PDE5 inhibitors even if the treatment is unsuccessful initially. Unilaterally nerve-spared patients and especially non-nerve-spared patients are likely to need more aggressive treatment.

AB - OBJECTIVE: Erectile dysfunction (ED) is common following radical prostatectomies, and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are generally considered the first choice of treatment. The purpose of this study was to analyze the long-term efficacy of PDE5 inhibitors in a group of men who did not achieve sufficient erectile function from the medication in the short term following surgery.MATERIALS AND METHODS: Prospectively collected data from patients with postprostatectomy ED, initial failure of PDE5-inhibitor treatment at 3 and/or 6 months and at least 12 months' follow-up were included. All patients had completed the International Index of Erectile Function short-form questionnaires (IIEF-5) before surgery and at follow-up visits. Response to PDE5 inhibitors was defined as an IIEF-5 score of at least 17.RESULTS: The inclusion criteria were fulfilled by 349 patients. At 12 months, 228 patients were still using PDE5 inhibitors. Of these patients, 92 had undergone bilateral and 120 had undergone unilateral nerve-sparing radical prostatectomies. Overall, 42 PDE5-inhibitor users (18%) were responders at 12 months. Bilateral nerve sparing was the only independent predictor of a late response (odds ratio = 2.9). Thus, 28% of bilaterally nerve-spared patients were responders, while corresponding numbers for unilaterally nerve-spared patients and non-nerve-spared patients were 13% and 6%, respectively.CONCLUSIONS: Patients who have undergone bilateral nerve-sparing radical prostatectomy should be rechallenged periodically with PDE5 inhibitors even if the treatment is unsuccessful initially. Unilaterally nerve-spared patients and especially non-nerve-spared patients are likely to need more aggressive treatment.

KW - Aged

KW - Erectile Dysfunction/drug therapy

KW - Humans

KW - Male

KW - Middle Aged

KW - Organ Sparing Treatments/methods

KW - Peripheral Nerves

KW - Phosphodiesterase 5 Inhibitors/administration & dosage

KW - Postoperative Complications/drug therapy

KW - Prostatectomy/adverse effects

KW - Retreatment

KW - Surveys and Questionnaires

KW - Time Factors

U2 - 10.1080/21681805.2017.1387603

DO - 10.1080/21681805.2017.1387603

M3 - Journal article

C2 - 29057723

SN - 0036-5599

VL - 52

SP - 108

EP - 110

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

IS - 2

ER -

Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater